NO20060329L - Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse - Google Patents
Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelseInfo
- Publication number
- NO20060329L NO20060329L NO20060329A NO20060329A NO20060329L NO 20060329 L NO20060329 L NO 20060329L NO 20060329 A NO20060329 A NO 20060329A NO 20060329 A NO20060329 A NO 20060329A NO 20060329 L NO20060329 L NO 20060329L
- Authority
- NO
- Norway
- Prior art keywords
- pth
- administered
- composition
- pharmaceutical compositions
- oral use
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 title 2
- 108090000445 Parathyroid hormone Proteins 0.000 title 2
- 239000000199 parathyroid hormone Substances 0.000 title 2
- 229960001319 parathyroid hormone Drugs 0.000 title 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 229910052791 calcium Inorganic materials 0.000 abstract 2
- 239000011575 calcium Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
Farmasøytisk sammensetning for oral administiering omfattende PTH, der in vitro fiigjøring av PTH - når den blir testet i en oppløsningstest av farmacopoeia standard - blir forsinket med minst 2 timer og med en gang fiigjøringen starter, blir minst 90% v/v slik som for eksempel, minst 99% av all PTH inneholdt i sammensetningen fiigjort i løpet av for det meste 2 timer. Sammensetningen kan også omfatte en kalsium inneholdende forbindelse og/eller et vitamin, D. Særlig blir PTH administiert i kombinasjon med en kalsium inneholdende forbindelse for behandling eller forhindring av ben-relaterte sykdommer, slik at I) en effektiv mengde PTH blir administiert for å senke plasmanivået av endogen PTH, og II) en effektiv mengde PTH bhr administiert for å oppnå en toppkonsentiasjon av PTH med en gang det endogene PTH-nivået er senket. Dette innebærer en potensiell terapeutisk eller profylaktisk kur for ben-relaterte forstyrrelser inkludert osteoporose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301035 | 2003-07-04 | ||
PCT/DK2004/000482 WO2005002549A1 (en) | 2003-07-04 | 2004-07-05 | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060329L true NO20060329L (no) | 2006-01-20 |
Family
ID=33560711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060329A NO20060329L (no) | 2003-07-04 | 2006-01-20 | Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070155664A1 (no) |
EP (1) | EP1643978A1 (no) |
JP (1) | JP2007525472A (no) |
KR (1) | KR20060105735A (no) |
CN (1) | CN1816324A (no) |
CA (1) | CA2531136A1 (no) |
IL (1) | IL172769A0 (no) |
NO (1) | NO20060329L (no) |
WO (1) | WO2005002549A1 (no) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
SI1915137T1 (sl) | 2005-08-10 | 2013-12-31 | Add Advanced Drug Delivery Technologies, Ltd. | Pripravek z nadzorovanim sproščanjem za peroralno dajanje |
RU2507196C2 (ru) | 2005-09-19 | 2014-02-20 | Эмисфире Текнолоджис, Инк. | Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты |
KR20140053419A (ko) * | 2005-11-17 | 2014-05-07 | 노파르티스 아게 | 약제학적 조성물 |
ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
ES2436028T3 (es) * | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
EP2762132A1 (en) | 2007-04-25 | 2014-08-06 | Cytochroma Inc. | Controlled Release 25-Hydroxyvitamin D |
DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
PL2215047T3 (pl) | 2007-11-02 | 2014-05-30 | Emisphere Tech Inc | Sposób leczenia niedoborów witaminy b12 |
WO2009137104A1 (en) * | 2008-05-09 | 2009-11-12 | Radius Health, Inc. | Combination therapy for breastcancer comprising an antiestrogenic agent |
AU2009283821B2 (en) * | 2008-08-18 | 2014-05-29 | Entera Bio Ltd. | Methods and compositions for oral administration of proteins |
US20100256060A1 (en) * | 2009-04-02 | 2010-10-07 | Unigene Laboratories Inc. | Peptide pharmaceuticals for nasal delivery |
US8682440B2 (en) | 2009-08-03 | 2014-03-25 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
BR112012003511A2 (pt) * | 2009-09-09 | 2019-09-24 | Asahi Kasei Pharma Corp | agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas |
WO2011048144A1 (en) * | 2009-10-20 | 2011-04-28 | Herbonis Ag | Composition comprising solanum glaucophyllum for preventing and/or treating hypocalcaemia and for stabilizing blood calcium levels |
FR2953139B1 (fr) * | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
CN102552919B (zh) * | 2010-12-15 | 2018-03-27 | 上海安博生物医药股份有限公司 | 一种给药组合物及其制备和使用方法 |
AU2010339907A1 (en) * | 2009-12-16 | 2012-07-05 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
US8562589B2 (en) | 2009-12-24 | 2013-10-22 | Rani Therapeutics, Llc | Swallowable drug delivery device and method of delivery |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
EP2568806B1 (en) | 2010-05-12 | 2016-05-11 | Radius Health, Inc. | Therapeutic regimens |
AU2011312490B2 (en) | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) * | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CN102144982B (zh) * | 2011-03-30 | 2012-12-12 | 江苏神龙药业有限公司 | 一种米诺膦酸片及其制备方法 |
US20150374725A1 (en) * | 2013-02-20 | 2015-12-31 | Prelief Inc. | Methods and compositions for treating and preventing intestinal injury and diseases related to tight junction dysfunction |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
PL3122426T3 (pl) | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
SG10201911274TA (en) | 2014-08-07 | 2020-02-27 | Opko Ireland Global Holdings Ltd | Adjunctive therapy with 25-hydroxyvitamin d |
JP6359390B2 (ja) * | 2014-09-05 | 2018-07-18 | テルモ株式会社 | インプラントデバイスおよびインプラントデバイス植え込み具 |
CA2975578A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
TWI747893B (zh) | 2016-03-28 | 2021-12-01 | 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 | 維生素d治療之方法 |
EP3474841B1 (en) | 2016-06-22 | 2022-03-16 | Ellipses Pharma Ltd | Ar+ breast cancer treatment methods |
MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
KR101796604B1 (ko) * | 2016-08-30 | 2017-11-10 | 목포대학교 산학협력단 | 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형 |
CN117417263A (zh) | 2017-01-05 | 2024-01-19 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
CN111372586B (zh) | 2017-11-20 | 2023-07-25 | 诺麦塔制药有限公司 | 包含chp的骨丢失疾病的预防、改善或治疗用组合物 |
CN112423844A (zh) | 2018-07-04 | 2021-02-26 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
US11857559B2 (en) * | 2018-09-10 | 2024-01-02 | Aurobindo Pharma Ltd. | Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof |
JP2022522550A (ja) * | 2019-03-08 | 2022-04-20 | アニヤ バイオファーム インク. | 副甲状腺ホルモンアナログの経口製剤および治療 |
KR102115353B1 (ko) * | 2019-05-17 | 2020-05-26 | 주식회사 노브메타파마 | Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
US20230151075A1 (en) * | 2019-12-03 | 2023-05-18 | The Johns Hopkins University | Parathyroid hormone attenuates low back pain and osteoarthritic pain |
WO2022133555A1 (pt) * | 2020-12-23 | 2022-06-30 | Lithocálcio Indústria, Comércio, Importação, Exportação E Representação Ltda. | Composição farmacêutica sólida contendo vitamina d e sal de cálcio, método para tratar ou prevenir condições relacionadas a baixa ingestão e/ou maior necessidade de cálcio, uso da composição farmacêutica sólida e produto farmacêutico ou suplementar |
KR20240013402A (ko) * | 2022-07-22 | 2024-01-30 | 주식회사 아이큐어비앤피 | 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
ATE195252T1 (de) * | 1993-04-23 | 2000-08-15 | Novartis Erfind Verwalt Gmbh | Wirkstoffabgabevorrichtung mit gesteuerter freigabe |
US6039975A (en) * | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
CN1228708A (zh) * | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
DE10013029A1 (de) * | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
-
2004
- 2004-07-05 JP JP2006517970A patent/JP2007525472A/ja not_active Withdrawn
- 2004-07-05 KR KR1020067000065A patent/KR20060105735A/ko not_active Application Discontinuation
- 2004-07-05 US US10/561,876 patent/US20070155664A1/en not_active Abandoned
- 2004-07-05 EP EP04738979A patent/EP1643978A1/en not_active Withdrawn
- 2004-07-05 CN CNA2004800191107A patent/CN1816324A/zh active Pending
- 2004-07-05 WO PCT/DK2004/000482 patent/WO2005002549A1/en active Application Filing
- 2004-07-05 CA CA002531136A patent/CA2531136A1/en not_active Abandoned
-
2005
- 2005-12-22 IL IL172769A patent/IL172769A0/en unknown
-
2006
- 2006-01-20 NO NO20060329A patent/NO20060329L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20070155664A1 (en) | 2007-07-05 |
IL172769A0 (en) | 2006-04-10 |
EP1643978A1 (en) | 2006-04-12 |
CA2531136A1 (en) | 2005-01-13 |
WO2005002549A1 (en) | 2005-01-13 |
JP2007525472A (ja) | 2007-09-06 |
KR20060105735A (ko) | 2006-10-11 |
CN1816324A (zh) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060329L (no) | Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse | |
Boursinos et al. | Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing | |
NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
KR950002150B1 (ko) | 레보도파 메틸에스테르를 함유하는 제약 조성물 | |
Quiding et al. | TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction | |
UA94916C2 (ru) | Композиция тразодона для введения один раз в день | |
ES2383433T3 (es) | Formulación farmacéutica de apomorfina para administración bucal | |
MXPA04012998A (es) | Modulares de receptores nucleares de hormonas esteroideas triciclicos. | |
RU2009111391A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
US6521266B1 (en) | Composition for growth hormone production and release, appetite suppression, and methods related thereto | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
CO4810383A1 (es) | Sal tartrato de un dipeptido sustituido | |
DE60041147D1 (de) | Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen | |
WO2012174158A2 (en) | Administration of benzodiazepine | |
HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
KR20050057673A (ko) | Jnk 억제제를 이용한 통증의 치료 | |
CA2486859A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
RU2007133435A (ru) | Способ комбинированного лечения и применимые для этого сочетания лекарственных средств | |
AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
EP1543826B1 (en) | Concentrated aqueous solution of ambroxol | |
ES2250726T3 (es) | Utilizacion de extractos de ginkgo biloba para preparar un medicamento destinado a tratar la sarcopenia. | |
EA038052B1 (ru) | Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли | |
US10456365B2 (en) | Methods and formulations for supporting and promoting bone health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |